Admin-Core-001

管理核心-001

• 批准号: 10710334
• 负责人: Ann Scheck McAlearney
• 金额: $ 43.97万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-18 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10710334
• 关键词: 2019-nCoV; Address; Antibodies; Antibody Response; Antigens; Applied Research; Archives; Basic Science; Behavioral; Bioinformatics; Biological Assay; Biometry; COVID-19; COVID-19 impact; COVID-19 pandemic; COVID-19 severity; Characteristics; Clinical; Clinical Services; Common Cold; Communicable Diseases; Communication; Communities; Cost Sharing; Data; Data Analyses; Disease; Disease Outcome; Educational workshop; Enzyme-Linked Immunosorbent Assay; Epidemiology; Facility Accesses; Fire - disasters; Fostering; Future; Gene Expression; Genetic; Goals; Health Services; Household; Immune; Immune response; Individual; Infection; Infrastructure; Institutes; Knowledge; Laboratories; Leadership; Longitudinal Studies; Maintenance; Methodology; Molecular; Monoclonal Antibodies; Natural History; Observational Study; Ohio; Outcome; Pathogenesis; Peripheral Blood Mononuclear Cell; Persons; Police; Prevalence; Process; Psychometrics; Public Health; Reagent; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Risk; Role; SARS-CoV-2 exposure; SARS-CoV-2 immune response; SARS-CoV-2 infection; SARS-CoV-2 pathogenesis; SARS-CoV-2 transmission; Sampling; Science; Serology; Serology test; Serum; Severity of illness; Test Result; Testing; Translational Research; Translations; United States Dept. of Health and Human Services; Universities; Vaccination; Vaccines; Viral; Virus; Work; biobank; biosafety level 3 facility; cohort; complex data; coronavirus disease; cost; data management; data quality; data sharing; design; first responder; high risk; implementation strategy; improved; improved outcome; innovation; insight; novel; pathogen; population health; respiratory virus; response; stem; synergism; transcriptomics; transmission process; virome; virtual

Overall Project Summary Stemming the spread of COVID-19 will require research that cross-cuts basic, translational, and applied sciences. The Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP- COVID) is proposed as a transdisciplinary entity to understand the interface between exposure risk, transmission, immune responses, disease severity, protection, and barriers to testing/vaccination, with the goal of improving population health and clinical outcomes. The Center will utilize state-of-the-art serological and molecular tests, developed at OSU, in a longitudinal study of first responders, a group at continual high risk of SARS-CoV-2 exposure, as well as their household contacts. Through the proposed work, STOP-COVID investigators will understand critical aspects of: (i) transmission in both asymptomatic and symptomatic individuals, (ii) immune, host, and viral determinants of disease outcome, and (iii) factors associated with immune protection. Center investigators will also identify best practices for communication of test results and information about COVID-19 to improve understanding of risk, transmission, and protection, while reducing access barriers to testing. The Center to STOP-COVID will: Aim 1 Develop Institute Infrastructure through three shared resource cores: 1. An Administrative Core that provides overall direction and leadership, coordinating all Center activities as well as Project–Core–SeroNet interactions; 2. A Testing and Biorepository Core, whose role is to perform first-tier serologic and viral testing during our longitudinal study using high throughput ELISA and neutralization assays developed at OSU, and cost-shared by OSU; and 3. A Data Management and Analysis Core that will provide project investigators with a centralized resource for biostatistics, bioinformatics, epidemiology, and psychometrics expertise. Aim 2: Conduct three innovative research projects to address: Project 1: Parallel serological and viral testing to determine COVID-19 prevalence, transmission, and protection in extended first responder cohorts. This project will also generate serology data for vaccines or mAbs, once available to this presumably high-priority group; Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection. This project will evaluate COVID-19 serological responses in the context of SARS-CoV-2 and common cold CoV (CCCoV) antibodies, using novel assays specific for a panel of antigens. Project 2 also will employ transcriptomics to understand how host genetics, CCCoV, other respiratory viruses, and immune responses contribute to pathogenesis; and Project 3: Responding to changing serological and viral information around COVID-19. This project will incorporate results from Projects 1 & 2 and SeroNet to inform best practices in risk communication, provide behavioral guidance to decrease transmission, and enhance protection from disease. Aim 3: SeroNet Participation and Sharing of Data and Best Practices. We will leverage STOP-COVID infrastructure to share data, results, reagents, and best practices with SeroNet, which will drive new discoveries and their translation into actionable strategies for implementation across all groups affected by COVID-19.

总体项目摘要 阻止COVID-19的传播将需要进行跨切割，翻译和应用的研究 科学。血清学检测中心改善了大流行期间的结局（停止） 提议COVID作为跨学科实体，以了解暴露风险，传播， 免疫反应，疾病的严重程度，保护和测试/疫苗接种障碍，目的是改善 人口健康和临床结果。该中心将利用最先进的血清学和分子测试， 在对第一反应者的纵向研究中，在OSU开发的一组SARS-COV-2的持续高风险 暴露及其家庭接触。通过拟议的工作，停止的调查人员将 了解以下方面的关键方面：（i）渐近和症状个体的传播，（ii）免疫， 疾病结局的宿主和病毒决定剂，以及（iii）与免疫保护相关的因素。中心 调查人员还将确定有关COVID-19的测试结果和信息的最佳实践 以提高对风险，传播和保护的理解，同时减少测试的访问障碍。 停止循环的中心将通过三个共享资源来开发研究所基础架构 核心：1。提供整体指导和领导的行政核心，协调所有中心活动 以及项目 - 核 - 螺旋体相互作用； 2。测试和生物座核，其作用是执行 在我们的纵向研究中，使用高通量ELISA和神经化的一级血清学和病毒测试 在OSU开发的测定，OSU的成本共享； 3。数据管理和分析核心将 为项目调查人员提供用于生物统计学，生物信息学，流行病学和的集中资源 心理计量学专业知识。目标2：进行三个创新研究项目以解决：项目1：平行 血清学和病毒测试以确定COVID-19的患病率，传播和保护性。 响应者队列。该项目还将生成疫苗或mAB的血清学数据，一旦可用 大概是高优先级组；项目2：COVID-19的严重程度和 免疫保护。该项目将在SARS-COV-2的背景下评估COVID-19的血清学反应 使用针对一组抗原的新颖测定法，和常见的冷COV（CCCOV）抗体。项目2也是如此 将采用转录组学来了解宿主遗传学，CCCOV，其他呼吸道病毒和免疫 反应有助于发病机理；和项目3：响应不断变化的血清学和病毒信息 在Covid-19。该项目将结合项目1和2和Seronet的结果，以告知最佳实践 在风险交流中，提供行为指导以减少传输并增强保护 疾病。目标3：Seronet参与和分享数据和最佳实践。我们将利用停车 与Seronet共享数据，结果，试剂和最佳实践的基础架构，这将推动新发现 以及他们转化为受COVID-19的所有群体实施的可行策略。